Novel diagnostic method
AssigneeProbiodrug AG
InventorsHolger Cynis, Martin Kleinschmidt, Kathrin Gans, Jens-Ulrich Rahfeld, Hans-Ulrich Demuth, Nadine Taudte
Life of this patent
Estimating the term…
Abstract
A method of monitoring treatment of an inflammatory disease or an inflammatory associated disease with the use of the ratio of N-terminal pyroglutamate modified MCP-1 (MCP-1 N1pE):total concentration of MCP-1 within a biological sample as a biomarker, and a method for determining the proportion of N-terminal pyroglutamate modified MCP-1 in relation to the total concentration of MCP-1 in biological samples. Also disclosed are a diagnostic kit and a method for screening a glutaminyl cyclase (QC) inhibitor or measuring the effectiveness of a glutaminyl cyclase (QC) inhibitor.
Claims32
A method of diagnosing or monitoring an inflammatory disease or an inflammatory associated disease or of response to treatment thereof, which comprises determining the proportion of N-terminal pyroglutamate modified MCP-1 in relation to the total concentration of MCP-1 within a biological sample.
A method of determining the effectiveness of a glutaminyl cyclase (QC) inhibitor within a biological sample and as a surrogate marker for glutaminyl cyclase (QC) inhibition within a treatment by QC inhibitor application.
A method of determining the proportion of N-terminal pyroglutamate modified MCP-1 in relation to the total concentration of MCP-1 within a biological sample which comprises the following steps:
- (a) determining a first concentration (ca) of N-terminal pyroglutamate modified MCP-1 in a biological sample;
- (b) determining a second concentration (cd) of total MCP-1 in said biological sample;
- and
- (c) determining the ratio of ca/cd, wherein the value of the first concentration (ca) is divided by the value of the second concentration (cd).
A method of screening for a glutaminyl cyclase (QC) inhibitor which comprises the steps of:
- (a) incubating a control sample comprising MCP-1 and glutaminyl cyclase (QC) and determining the proportion of N-terminal pyroglutamate modified MCP-1 in relation to the total concentration of MCP-1;
- (b) incubating a control sample with a mixture comprising MCP-1 and glutaminyl cyclase (QC) together with a glutaminyl cyclase (QC) inhibitor and determining the proportion of N-terminal pyroglutamate modified MCP-1 in relation to the total concentration of MCP-1;
- such that a reduction in the ratio of N-terminal pyroglutamate modified MCP-1:total MCP-1 in step (b) relative to step (a) is indicative of glutaminyl cyclase inhibition.
A method for measuring the effectiveness of a glutaminyl cyclase (QC) inhibitor which comprises incubating a glutaminyl cyclase (QC) inhibitor with a mixture comprising MCP-1 and glutaminyl cyclase (QC) and determining the proportion of N-terminal pyroglutamate modified MCP-1 in relation to the total concentration of MCP-1.
A method of monitoring efficacy of a therapy in a subject having, suspected of having, or of being predisposed to, an inflammatory disease or an inflammatory associated disease, comprising determining the proportion of N-terminal pyroglutamate modified MCP-1 in relation to the total concentration of MCP-1 in a biological sample from a test subject.
Dependencies are inferred from the claim text.